Copiktra (duvelisib)

News alerts, weekly reports and conference planners

Company:

CSPC Pharma, Sanofi, Secura Bio, Verastem, Yakult Honsha

Drug class:

PI3Kδ inhibitor, PI3Kγ inhibitor

Related drugs:

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
CXCL11 elevation	Follicular Lymphoma	CXCL11 elevation	Follicular Lymphoma	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3
IL2RA elevation	Follicular Lymphoma	IL2RA elevation	Follicular Lymphoma	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3	duvelisib Resistant: C3 – Early Trials duvelisib Resistant : C3
Chr del(6q)(q15)	Follicular Lymphoma	Chr del(6q)(q15)	Follicular Lymphoma	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3	venetoclax + duvelisib Sensitive: C3 – Early Trials venetoclax + duvelisib Sensitive : C3
PIK3CD expression	Squamous Cell Carcinoma of Head and Neck	PIK3CD expression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CG expression	Squamous Cell Carcinoma of Head and Neck	PIK3CG expression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CG overexpression	Squamous Cell Carcinoma of Head and Neck	PIK3CG overexpression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CD overexpression	Squamous Cell Carcinoma of Head and Neck	PIK3CD overexpression	Squamous Cell Carcinoma of Head and Neck	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CG overexpression	Melanoma	PIK3CG overexpression	Melanoma	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CD overexpression	Melanoma	PIK3CD overexpression	Melanoma	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CG expression	Melanoma	PIK3CG expression	Melanoma	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
PIK3CD expression	Melanoma	PIK3CD expression	Melanoma	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D
Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	duvelisib Resistant: D – Preclinical duvelisib Resistant : D	duvelisib Resistant: D – Preclinical duvelisib Resistant : D
ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	duvelisib Resistant: D – Preclinical duvelisib Resistant : D	duvelisib Resistant: D – Preclinical duvelisib Resistant : D
KLRG1 expression	Lymphoma	KLRG1 expression	Lymphoma	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D	duvelisib Sensitive: D – Preclinical duvelisib Sensitive : D

Copiktra (duvelisib)

Associations
(26)

Associations
(26)

Copiktra (duvelisib)

Associations(26)

Associations(26)

Associations
(26)

Associations
(26)